Immorta Bio has completed preclinical work on SenoMune-0257, a nine-amino-acid peptide designed with AI to restore immune recognition of senescent cells, with clinical development planned for 2026. In laboratory studies the peptide stimulated cytotoxic T cells that cleared senescent cells while sparing healthy ones, and was engineered for durable immunological memory and lower off-target toxicity than small-molecule senolytics. Safety and efficacy in humans have not been established.
Key Points
- AI-designed peptide directs cytotoxic T cells toward senescent cells
- Preclinical data show selective clearance, healthy cells spared
- Off-the-shelf synthetic format targets clinical development in 2026
Longevity Analysis
Senescent cell accumulation is driven in part by declining immune surveillance with age, so restoring the body's own recognition and clearance capacity addresses the upstream failure rather than repeatedly dosing a drug to compensate for it. An immunological approach promising durable memory would shift senolytic strategy from intermittent pharmacological clearance toward sustained defensive competence, with implications for tissue repair capacity and inflammatory burden. The distinction matters clinically: selectivity and off-target profile determine whether such interventions can be used long enough, and consistently enough, to alter trajectory.
Original published by LT Wire.